Nektar Therapeutics (NKTR) Receives Price Target

Nektar Therapeutics (NKTR) : Average target price received by Nektar Therapeutics (NKTR) is $19.33 with an expected standard deviation of $3.56. The most aggressive target on the stock is $25, whereas the most downbeat target is $14. 6 financial analysts are currently covering the stock.

Nektar Therapeutics (NKTR) : The consensus on Nektar Therapeutics (NKTR) based on 7 analyst recommendation on the company stock is 1, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 4 which endorses a Sell on the stock. However, 7 brokers have a differing view as they consider the stock to be a Strong Buy at current levels.


Nektar Therapeutics (NASDAQ:NKTR): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $17.85 and $17.59 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $18.12. The buying momentum continued till the end and the stock did not give up its gains. It closed at $18.11, notching a gain of 1.46% for the day. The total traded volume was 1,164,150 . The stock had closed at $17.85 on the previous day.

Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Companys pipeline is comprised of drug candidates for therapeutic areas, including oncology, pain, anti-infectives, and immunology. The Companys research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its polymer chemistry platform is being used to create specialized therapeutics, including small molecule oral and parenteral drugs, proteins, peptides and antibody fragments.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.